PULSENMORE
Sector: Healthcare & Life Sciences
About PULSENMORE
Pulsenmore (Nasdaq: PLSM) is a pioneer in remote ultrasound technology. On February 2, 2026, the company announced its first US commercial agreement with the Center for Fetal Medicine (CFFM) in Los Angeles, allowing patients to perform remote fetal monitoring from home following its recent FDA clearance.
Products
Pulsenmore home ultrasound platform
A practical, safe, and effective solution for prenatal telehealth and remote sonographic fetal well-being assessment, with evidence suggesting better resource management and increased patient engagement and satisfaction. Pulsenmore allows patients to perform basic ultrasound assessments from the comfort of their homes with remote clinician guidance. The real-time teleultrasound consultation allows online guiding and controlling the duration and frequency of the patient’s scans. The system also allows adjustment of the ultrasound settings for each scan remotely. App-guided mode. The patient follows self-scan protocols on the Pulsenmore mobile app, developed by OBGYN specialists. Scans are then uploaded to the cloud for asynchronous review by clinicians, allowing for evaluation of fetal movement, fetal heart activity, and amniotic fluid.